Grant of share option

LIDCO GROUP PLC

("LiDCO" or the "Company")

Grant of share option

LiDCO Group Plc (AIM:LID), the UK-based hemodynamic company, today announces that on 24 April 2012, in accordance with the rules of the Company's Share Option Schemes, options were granted to two Directors to subscribe for new ordinary shares of 0.5 pence each ("Ordinary Shares") in the Company. The options are exercisable at 18 pence per Ordinary Share for a period of seven years from 24 April 2015. The allocations are set out below:

Director Number of Total number Number of Percentage of

Options of Options shares held existing share

granted now held capital

_____________________________________________________________________

John Barry 100,000 3,480,767 475,139 0.27%

Paul Clifford 76,833 796,483 600,000 0.34%

In addition, share options over a further 1,100,566 new Ordinary Shares have been granted to employees of the Company on the same terms as above.

- Ends -

For further information, please contact:

Media enquiries:

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of adult hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology can significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's sales office is in Cambridge, its manufacturing facility / general administration base is in Hoxton, London, and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management. The monitor enables acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being both during and after surgery. These benefits are:

* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid.

* LiDCOview:an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

* LiDCO's Distribution Network:

The Company sells via its own direct sales force to hospitals in the UK, and in export markets predominantly through a worldwide network of speciality critical care and anesthesia distributors.